Immunovant heads into the final weeks of September with an unusual tension: options traders are the most bullish they have been all year, yet short sellers have quietly been adding to positions over the past month.
The options market is sending a strikingly one-sided signal. The put/call ratio dropped to 0.26 this week — nearly three standard deviations below its 20-day average of 0.28, making it the most call-skewed reading of the past 52 weeks (the full-year low is 0.05, the high 0.61). That is an unusually aggressive lean toward upside positioning, suggesting a subset of market participants is looking for a catalyst to the upside ahead of the November 6 earnings print.
Short interest tells a different story. Bears have been adding steadily — SI has climbed to 9.6% of the free float, up roughly 7% over the past month and nearly 3% on the week alone. That is a meaningful build in a name where conviction on either side tends to amplify moves. The borrow market, however, is not under pressure. Availability runs at 679%, well within the normal range and far above the 52-week tightest reading of 193% — meaning there is ample supply for new shorts to enter without paying up. Cost to borrow is just 0.46%, barely changed from its range over the past six weeks. The ORTEX short score has drifted higher to 67.9, its best reading of the recent window, consistent with the gradual increase in short positioning. Notably, the stock itself is up only 1.7% on the week and has given back 16% over the past month, so the short rebuild is running into a stock that has already corrected materially from recent highs.
The Street has been broadly constructive for much of the year, though the most recent bellwether move is from JP Morgan, whose analyst raised the target from $47 to $50 in early August while holding the Overweight rating — a signal of confidence even after the rally. Citi and Guggenheim both have Buy ratings with targets in the $61–62 range. Goldman Sachs sits at Neutral with a $32 target, and Truist holds at $30. The consensus sits at Hold, skewed by the wide gap between the bulls and the cautious minority. At $37.29, the stock trades meaningfully above the bear targets, but well below what the Buy-side analysts have penciled in. The bull case centres on IMVT-1402 as a potential first-in-class FcRn inhibitor in autoimmune disease, with multiple upcoming trial readouts as catalysts. The bear case is narrower but pointed: Phase 2 statistical design creates real risk of a period-2 miss, and the company's entire financial stability rests on the clinical outcome of a single asset.
Ownership is notably concentrated. Roivant Sciences holds 54.9% of shares and has filed a Schedule 13D — the activist-intent filing — making it the most important structural fact about this register. Roivant's stake has edged down slightly from 56.9% to 55.9% per the most recent filing (December 2025), but the 13D designation means it retains active intent around the position. Separately, Farallon Capital added aggressively in the June quarter, picking up 4.26 million shares to build a 2.8% stake. BlackRock and T. Rowe Price also added in the most recent period. The institutional flow picture has been broadly accumulative at the fund level, even as the stock has pulled back. As a standard caveat, 13D/G positions are disclosed around the 5% threshold and may not reflect current levels. On the insider side, the 90-day net is negative — roughly $4.5 million sold in aggregate — though much of the activity involves the CTO and CFO executing discretionary sales rather than a coordinated exit. The COO's $135,000 sale in late August was not covered by a 10b5-1 plan, which makes it slightly more notable in signal terms.
The next catalyst is the November 6 earnings event. The prior two prints produced modest one-day moves — down 2% in September and up 1.7% in August — but five-day drifts have been more meaningful, with a 6.5% gain after the August print. With SI approaching 10% of float, call positioning at a year low, and a key data readout window approaching, the November print will be watched as much for pipeline newsflow as for the quarterly financials.
See the live data behind this article on ORTEX.
Open IMVT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
